Is Caffeine an Environmental Modifier in Huntington's Disease?
NCT ID: NCT03034122
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
77 participants
OBSERVATIONAL
2017-10-11
2024-04-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* premanifest (total motor UHDRS \< 5)
* estimated time to diagnosis between 3 and 10 years
* adults older than 21 years (in order to exclude juvenile patients who begin the disease before 21 years)
* informed consent signed
* with a social protection
Exclusion Criteria
* pregnant and lactating women
* People under guardianship, trusteeship, deprive of freedom
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clémence Simonin, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Amiens
Amiens, , France
CHU de Angers
Angers, , France
CHU Pellegrin
Bordeaux, , France
CHU de Grenoble
Grenoble, , France
Hôpital Roger Salengro, CHRU
Lille, , France
CHU Montpellier
Montpellier, , France
CHU de Nancy
Nancy, , France
AH-HP La Pitié-Salpétrière
Paris, , France
AH-HP, Hôpital Henri Mondor
Paris, , France
CHU Purpan
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-A00892-49
Identifier Type: OTHER
Identifier Source: secondary_id
2015_67
Identifier Type: -
Identifier Source: org_study_id